VOLITIONRX LTD

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

VNRX$0.18-7.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	For the Years Ended
	December 31,2025	December 31,2024
	$	$
Revenues
Service	450,805	228,138
Product	1,276,579	1,005,373
Total Revenues	1,727,384	1,233,511
Operating Expenses
Research and development	10,081,299	14,406,486
General and administrative	9,463,581	8,487,562
Sales and marketing	3,921,075	5,364,433
Total Operating Expenses	23,465,955	28,258,481
Operating Loss	(21,738,571)	(27,024,970)
Other Income (Expenses)
Grant income	516,515	103,368
Gain /( Loss) on disposal of fixed assets	1,829	(34,731)
Interest income	600	9,947
Interest expense	(532,192)	(340,362)
Amortization of debt discount	(1,957,147)	-
Gain on change in fair value of warrant liability	76,908	28,763
Gain on change in fair value of derivative liability	128,729	-
Total Other Income (Expenses)	(1,764,758)	(233,015)
Net Loss	(23,503,329)	(27,257,985)
Net Loss attributable to Non-Controlling Interest	146,302	290,149
Net Loss attributable to VolitionRx Limited Stockholders	(23,357,027)	(26,967,836)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	(680,702)	141,691
Net Comprehensive Loss	(24,184,031)	(27,116,294)
Loss Per Common Share Attributable to Common Stockholders - Basic and Diluted	(0.22)	(0.31)
Weighted Average Shares Outstanding – Basic and Diluted	106,832,140	86,531,172

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.